Article

Pfizer withdraws application

Pfizer has withdrawn its application to the European Medicines Agency for an extension of the therapeutic indication for 0.3-mg pegaptanib sodium (Macugen) injection to include treatment of visual impairment due to diabetic macular edema (DME).

London-Pfizer has withdrawn its application to the European Medicines Agency for an extension of the therapeutic indication for 0.3-mg pegaptanib sodium (Macugen) injection to include treatment of visual impairment due to diabetic macular edema (DME).

The company had submitted the application in June 2010, and the agency’s Committee for Medicinal Products for Human Use (CHMP) was reviewing it. Pfizer said that it withdrew its application because the CHMP believed it could not reach a conclusion on a positive benefit-risk balance for DME based on the data provided. The withdrawal of an application does not preclude the possibility of the company filing a new application later.

In the European Union, pegaptanib is approved for the treatment of neovascular age-related macular degeneration.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.